Catalyst Wire Dossier Catalyst Wire Dossier

Crenezumab

· Genentech, Inc.
Drug timelines are a Plus or Pro feature.

7 regulatory and trial events tracked for Crenezumab, covering 2016-11-02 to 2024-03-15. Get the full timeline:

Most recent: Clinical Trial Update: Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease [Phase 2]

See pricing